OVIDE
LOE Approachingmalathion
NDATOPICALLOTION
Approved
Aug 1982
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
4/8 — Partial
OVIDE (malathion) is cholinesterase inhibitors [moa]. First approved in 1982.
Drug data last refreshed 14h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVIDE (malathion) is a topical lotion cholinesterase inhibitor approved in 1982 for parasitic infections, primarily head lice. It works by inhibiting acetylcholinesterase, disrupting neurotransmission in target parasites. The product is a legacy small-molecule therapeutic approaching loss of exclusivity.
LOE Approaching4mo to LOE
Low commercial velocity with only 1 linked job posting; small product team focused on maintenance and compliance rather than growth initiatives.
Mechanism of Action
Cholinesterase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak
0
Postherpetic Neuralgia
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
Lung Diseases, Interstitial
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
COVID-19
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
Squamous Cell Carcinoma of the Anal Canal
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Polycythemia Vera
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.